IL1A (Interleukin 1, alpha)

Oxidation levels decreased after immunotherapy (p = 0.04) and increased only in non-responder patients (p = 0.02). Oxidative stress may be indirectly affected by immunotherapy and could serve as a novel tool to identify responding patients in the NSCLC setting.

Findings of this study emphasize the importance of gene polymorphisms which encode inflammatory interleukins in the severity of pain and response to palliative radiotherapy. Regional research ethical committee number BE-2-39 ClinicalTrials.gov registration number NCT02024815.

It also shows the usefulness of network toxicology in evaluating health risks from environmental chemicals. These findings may help guide future efforts in prevention and treatment strategies.

Elevated prolidase activity, along with increased oxidative stress and inflammatory markers in silica-exposed individuals and silicosis from the study, suggests a potential role of prolidase in the pathogenesis of silicosis. These findings may contribute to understanding the molecular mechanisms underlying silica-induced lung injury, though further research is needed to establish its prognostic utility.

We identified transient and sustained proteomic shifts that trace coordinated changes in oxidative stress, heme metabolism, and metabolic adaptation, alongside key regulators such as IL1A, TNF, EHF, PPARD, and TXNIP. The progression from early injury-related divergence to partial recovery by day 8 highlights the dynamic nature of post-insult remodeling. These findings support urinary proteomics as a robust, non-invasive tool for probing HIE pathophysiology and point to promising biomarker and pathway candidates for future studies.

Multiple drugs including chlorogenic acid (PubChem CID: 1794427), losartan (PubChem CID: 3961), and estrone sulfate (PubChem CID: 3001028), were found to potentially exhibit synergistic effects with theophylline. This finding provides a key scientific basis for repurposing the drug. Furthermore, a drug combination discovered through multiomics analysis and laboratory tests offers a direct and practical new path for developing new combination therapies for hepatocellular carcinoma in the clinic.

Among the top pathways identified based on FDR and P value were receptor binding signaling, regulation of cell migration, the extracellular matrix, and the AGE-RAGE signaling pathway. The results predict that the hub genes correlated with angiogenesis may serve as potential therapeutic targets or could be biomarkers for breast cancer.

Also, RNA-seq analyses indicated that while Sarm1 deficiency protected from IL1A+TNF induced RGC loss it did not significantly alter microglia and astrocyte responses. Altogether, these findings indicate that IL1A potentiates SARM1-dependent TNF-induced RGC death in vivo.

Trogocytosis-related CLDN18.2 inhibited the glucose uptake, glycolysis and cytotoxicity of tumour-infiltrating CD8+ T cells by promoting the ubiquitin-proteasomal degradation of β-catenin in PDAC. Therefore, targeting trogocytosis-related CLDN18.2+CD8+ T cells may be a promising therapeutic strategy to inhibit PDAC progression.

We developed a viable in vitro model to study contact-compression, showing biomechanical inflammatory and remodeling responses. With adjustable components, this model can be applied to further study tissue responses to lung implants.

Key prognostic genes, including SLC2A1, SLC16A1, IL1A, AHSG, and ALOX15, were validated through RT-qPCR. This study highlights the molecular heterogeneity of propionate metabolism in LUAD and proposes a prognostic signature that could inform immunotherapeutic stratification.

Low levels of miR-323b-5p predict a poor prognosis for NSCLC. miR-323b-5p regulates the cell cycle of NSCLC cells by targeting IL1A, thereby inhibiting cell proliferation.